Published Manuscripts (2004)
Palmer AJ, Roze S, , Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Current Medical Research and Opinion 2004; 20(11): 1729-46
Palmer AJ, Roze S, , Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion 2004; 20(S1): S5-26
Palmer AJ, Roze S, , Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Current Medical Research and Opinion 2004; 20(S1): S27-40
Palmer AJ, Roze S, Lammert M, , Minshall ME, Nicklasson L, Gall MA, Spinas GA. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Current Medical Research and Opinion 2004; 20(S1): S41-51
Palmer AJ, Roze S, , Minshall ME, Hayes C, Oglesby A, Spinas GA. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Current Medical Research and Opinion 2004; 20(S1): S52-58
Palmer AJ, Roze S, , Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model. Current Medical Research and Opinion 2004; 20(S1): S59-66
Palmer AJ, Roze S, , Minshall ME, Lammert M, Nicklasson L, Spinas GA. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Current Medical Research and Opinion 2004; 20(S1): S67-73
Palmer AJ, Roze S, , Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical Therapeutics 2004; 26(2): 304-21
Dial with SkypeOut